The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2022 | Identifying high-risk multiple myeloma & improving treatment strategies in this patient population
In this discussion, Heinz Ludwig, MD, Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria, and Meral Beksac, MD, Ankara University, Ankara, Turkey, explore the different parameters that can be used to define high-risk multiple myeloma, including genetic, clinical, and biological features, and discuss optimal treatment strategies for this patient population, commenting on the possibility of incorporating bispecific antibodies and CAR-T therapy in the treatment regimen of patients with high-risk disease, and briefly discussing the prognostic value of sustained measurable residual disease (MRD) negativity in these patients. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
